Cryosite Limited · ASX:CTE
Cryosite — Investor Presentation (August 2024)
24 slides from Cryosite's investor presentation, Aug 20, 2024
Slide 1: Corporate Presentation Cryosite Limited
For personal use only Corporate Presentation Cryosite Limited August 2024 ASX Code: CTE www.cryosite.com
Slide 2: Disclaimer
Disclaimer The following disclaimer applies to this non-confidential presentation prepared by Cryosite Limited ACN 090 919 476 (Cryosite) which is dated 7 May 2024 (Presentation). By accepting or receiving this Presentation, you acknowledge and agree to the terms set out below. Summary information T
Slide 3: Investor Enquiries
Investor Enquiries For enquiries, please contact: For personal use only Andrew Kerr Executive Director Email: akerr@bercon.com.au Phone: 0483 840 860 3
Slide 4: FY24 Highlights
FY24 Highlights An exceptional year for Cryosite NPAT of $1.8m - an increase of 31% on prior year For personal use only EBITDA of $2.8m – an increase of 28% on prior year Revenue from ordinary activities $12.6m - an increase of 6% on prior year Earnings per share of 3.77 cents - an increase of 31% f
Slide 5: Leadership Team
Leadership Team Experienced leadership team driving the business Experienced board of directors …with a talented management team For personal use only Mark Kerr Scott Thomas Andrew Kerr Alicia Steel, PhD (USyd) Jane Hao Chairman of the Board Non-Executive Director Executive Director General Manager
Slide 6: Investment Highlights
Investment Highlights Leading Australian clinical trials logistics, storage and distribution company Over 23 years operating in the clinical trials and biological storage businesses For personal use only Leading clinical trial Highly regulated, specialist storage and logistics solutions to the c
Slide 7: Business Segments
Business Segments Cryosite operates through the following two business segments For personal use only cord blood Clinical Trial Logistics Biological Storage Cord Blood and Tissue Storage Independent supply chain expertise and third-party depot Specialist temperature-controlled storage provider speci
Slide 8: Broad Scope of Clinical Trial Logistic Services
Broad Scope of Clinical Trial Logistic Services Cryosite offers a board range of services Characteristics of the services For personal use only Inventory Control Reporting Reconciliation Web Portal Access Dry Shipping Clinical trial logistics Destruction Secure Witnessed Validated Supplier Certified
Slide 9: Market Overview: Poised for Growth
Market Overview: Poised for Growth 2028 Global Clinical Trials Market Forecast1,2 For personal use only Global Clinical Trial market A$111bn CAGR 8.7% Global clinical trial supply o Australian R&D tax credit continues to make it attractive and logistics A$10.4b for overseas and domestic life science
Slide 10: Barriers to Entry
Barriers to Entry Significant barriers to entry creates a competitive advantage Cryosite holds regulatory licenses that can take 2+ years to achieve. For personal use only GMP and GWP licenses are required to support the specialised needs of highly regulated, temperature-sensitive therapeutic produc
Slide 11: Facility
Facility Purpose-built, modern facility licenced by the TGA 2,100m2 GMP and GWP-certified facility For personal use only Secure site: > Back to base intrusion alarms > 24 hour / 7-day monitoring > Card access > Security Patrols 24-hour temperature monitoring Independent backup power by two generator
Slide 12: Clinical Trial Services Segment
For personal use only Clinical Trial Services Segment 12
Slide 13: Clinical Trial Services
Clinical Trial Services Specialist temperature-controlled storage, logistics and distribution services For personal use only Manage the entire clinical trial supply chain: Validated Inventory Management System and Quality Management System Receipt, retention & distribution of clinical supplies Label
Slide 14: Clinical Trial Services Specifications
Clinical Trial Services Specifications Cryosite currently manages 650+ clinical trials For personal use only 650+ 9,300+ 99.97%2 shipments per annum, managing on-time dispatch rate 90% temperature current trials1 for shipments managed ~25% 20% All market share in market share of required licences he
Slide 15: Clinical Trial Customers
Clinical Trial Customers High quality customer and end user base For personal use only End Users of Direct Customers Customer Pharmaceuticals 11 of the top Universities Industry leading global 15 companies base CROs & CMOs Local and Research international Hospitals companies clients 15
Slide 16: Biological Storage Segment
For personal use only Biological Storage Segment 16
Slide 17: Biological Storage Capabilities
Biological Storage Capabilities Specialist temperature-controlled storage Expertise, facilities, personnel and systems to provide a wide range of biological storage services for: For personal use only Haematopoietic Cellular & Tissue Mesenchymal PK/PD Progenitor Cells Storage Stem Cells Samples Mast
Slide 18: Biologics Specifications
Biologics Specifications Cryosite operates out of a state-of-the-art 2,100m2 facility For personal use only 2,100m2 33 20 GMP and GWP LN2 tanks -80°C freezers licensed site facility 7.5% 10 market share for -20°C freezers 4 biological storage in (including 2 being cold rooms Australia, and growing d
Slide 19: Cord Blood and Tissue Storage Segment
For personal use only Cord Blood and Tissue Storage Segment 19
Slide 20: Overview
Overview Experts in cord blood and tissue storage For personal use only 1st 20+ Australian cord blood years’ experience service provider ~17,000 Therapeutics current customers accredited license (cord blood stored) 20
Slide 21: Cord Blood Use
Cord Blood Use One of the richest sources of stem cells, which have huge potential in the treatment of diseases For personal use only • Umbilical cord blood is one of the richest sources of stem cells • Stem cells in cord blood have huge potential to treat chronic diseases such as cancer, diabetes,
Slide 22: Financials
For personal use only Financials 22
Slide 23: Historical Financials
Historical Financials Record financial results for FY24 Segmented Revenue (A$m)1,2 For personal use only Clinical Trials and Biological Services Cord Blood and Tissue Storage Unallocated • EBITDA growth of ~176% since 2H FY20 (as at 2H FY24) 6.2 6.4 6.2 5.9 5.1 5.8 5.7 1.2 1.1 1.2 • Organic growth i
Slide 24: For personal use only
For personal use only ‘eryosite professional, dependable, compliant